Imunon Inc美股招股说明书(2025-07-22版)

with the ATM Prospectus Supplement, the “Prospectus”) filed as part of our registration statement on Form S-3 (File No. 333-279425)(the “Registration Statement”), relating to the offer, issuance and sale of shares of our common stock, par value $0.01 per share(“Common Stock”), from time to time pursuant to the terms of an At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales Agreement”),by and between us and H.C. Wainwright & Co., LLC, as sales agent or principal (“Wainwright” or the “sales agent”). Through the date hereof, we have sold an aggregate of $1,815,267 of shares of our Common Stock through the sales agent under the Sales Agreement.This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to theextent that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement isnot complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments orsupplements thereto.We are filing this prospectus supplement to amend and supplement the Prospectus to increase the aggregate amount we intend to sellpursuant to the Sales Agreement. As of the date of this prospectus supplement, we are offering up to an aggregate of $10,000,000 ofour Common Stock for sale under the Sales Agreement, which includes $5,500,000 that was originally authorized pursuant to the ATM Common Stock on The Nasdaq Stock Market LLC (“Nasdaq”) on June 2, 2025. As a result, our public float has increased above $75.0million, and we are no longer subject to the limitations contained in General Instruction I.B.6 of Form S-3 as of the date of thisprospectus supplement. If we become subject to the offering limits in General Instruction I.B.6 of Form S-3 in the future, we will fileanother prospectus supplement. The validity of the shares being offered hereby will be passed upon by Thompson Hine LLP.Investing in our securities involves a high degree of risk. Before making an investment decision, please read “Risk Factors”beginning on page S-3 of the ATM Prospectus Supplement and the other documents and information contained orincorporated by reference in this prospectus supplement and the ATM Prospectus Supplement. H.C. Wainwright & Co. The date of this prospectus supplement is July 22, 2025